Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer.
A Pilot Study of the Herbal Remedy Essiac (ESIAK ®) Versus Placebo in Improving the Quality of Life in Women Completing Adjuvant Treatment for Breast or Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers.
Sponsor: Women and Infants Hospital of Rhode Island
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Women and Infants Hospital of Rhode Island
- Apnea of Prematurity · Phase NA · Jun 2020
- Gestational Diabetes · Phase PHASE3 · Jul 2019
- Heavy Menstrual Bleeding · Phase NA · Dec 2018
- Infertility · Phase PHASE3 · Dec 2011
See all terminations from Women and Infants Hospital of Rhode Island
A NA clinical study on Breast Cancer and Ovarian Cancer, this trial is terminated or withdrawn. The trial is conducted by Women and Infants Hospital of Rhode Island and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2021 — Jul 2024 [monthly]
Terminated NA
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Jan 2017 — Jun 2018 [monthly]
Terminated NA
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Women and Infants Hospital of Rhode Island
For direct contact, visit the study record on ClinicalTrials.gov .